机构：[1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China[2]Integrated Hospital of Traditional Chinese Medicine, SouthernMedicalUniversity, Guangzhou, Guangdong, China[3]School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
Diagnosis of gastric intestinal metaplasia (GIM) relies on gastroscopy and histopathologic biopsy, but their application in screening for GIM is limited. We aimed to identify serological biomarkers of GIM via screening in Guangdong, China.
Cross-sectional field and questionnaire data, demographic information, past medical history, and other relevant data were collected. Blood samples were collected for pepsinogen (PG)I, PGII, gastrin-17, and Helicobacter pylori antibody testing, and gastroscopy and histopathologic biopsy were performed. Single factor and logistic regression analyses were used to evaluate the correlation between these indicators and GIM, and decision tree models were used to determine the cut-off points between indicators.
Of 443 participants enrolled, 87 (19.6%) were diagnosed with GIM. Single factor analysis showed that pepsin indicators (PGI, PGII, and PGI/PGII ratio) and the factors Mandarin as native language, urban residency, hyperlipidemia, and age were associated with GIM. Logistic regression analysis showed that PGI and age were associated with GIM.
Age is an important factor for predicting GIM progression; age >60 years increased its risk. Detection of GIM was higher in individuals with PGI levels >127.20 ng/mL, which could be used as a threshold indicating the need to perform gastroscopy and histopathologic biopsy.
基金：
This work
was supported by a fund from Science,
Technology & Innovation Commission of
Guangzhou Municipality, the project of people’s
livelihood science and technology (no.
201803010037).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
第一作者：
第一作者机构：[1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China[2]Integrated Hospital of Traditional Chinese Medicine, SouthernMedicalUniversity, Guangzhou, Guangdong, China
通讯作者：
通讯机构：[1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China[*1]Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, No. 19, Nonglinxia Road, Yuexiu District, Guangzhou, Guangdong Province 510080, China.
推荐引用方式(GB/T 7714)：
Xujuan Liu,Min Zhang,Riyu Luo,et al.Significance of pepsinogen in screening for gastric intestinal metaplasia in Guangdong, China.[J].The Journal of international medical research.2021,49(2):300060521990495.doi:10.1177/0300060521990495.
APA：
Xujuan Liu,Min Zhang,Riyu Luo,Keran Mo&Xingxiang He.(2021).Significance of pepsinogen in screening for gastric intestinal metaplasia in Guangdong, China..The Journal of international medical research,49,(2)
MLA：
Xujuan Liu,et al."Significance of pepsinogen in screening for gastric intestinal metaplasia in Guangdong, China.".The Journal of international medical research 49..2(2021):300060521990495
